Metformin Prostate Cancer Adjuvant Trial

Summary

This is a Phase II clinical study to determine if Metformin can increase Prostate Specific Antigen (PSA) doubling time for patients with Prostate Cancer who have failed primary treatment with radiation, or surgical patients that are at high risk for recurrence based on surgical pathology. Men with confirmed prostate cancer and rising serum PSA levels will receive Metformin and will be monitored for PSA response and disease progression.

Timeline

Start

2014-06

Primary completion

2021-07-21

Completion

2021-07-21

Drugs

Indications